Few studies have examined abuse of prescription opioids among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. The current 7-week inpatient study assessed oral oxycodone self-administration by patients with chronic pain who had a history of opioid abuse. Participants (n = 25) were transitioned from their preadmission prescribed opioid to Bup/Nx. All of the participants were tested under each of the sublingual Bup/Nx maintenance doses (2/0.5, 8/2 or 16/4 mg) in random order. During each maintenance period, participants could self-administer oxycodone orally (0, 10, 20, 40 or 60 mg prescription opioids) or receive money during laboratory sessions. Drug choice (percentage) was the primary dependent variable. Subjective ratings of clinical pain and withdrawal symptoms also were measured. Mann-Whitney tests compared percentage of drug choice for each active oxycodone dose to placebo. Logistic regression analyses identified correlates of oxycodone preference, defined as 60% or greater choice of oxycodone compared to money. Pain was significantly reduced while participants were maintained on Bup/Nx compared to preadmission ratings. No differences in percentage drug choice were observed between the active oxycodone doses and placebo under each Bup/Nx maintenance dose. However, factors associated with oxycodone preference were lower Bup/Nx maintenance dose, more withdrawal symptoms and more pain. These data suggest that Bup/Nx was effective in reducing pain and supplemental oxycodone use. Importantly, adequate management of pain and withdrawal symptoms by Bup/Nx may reduce oxycodone preference in this population.
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Introduction
In the United States, the problem of nonmedical use of prescription opioids has emerged as a major public health issue [1] . Other countries, such as Australia, New Zealand [12] and Canada [33] , also are concerned about the phenomenon of prescription opioids abuse. In the United States, oxycodone and hydrocodone are among the most commonly prescribed or regularly used opioids, as well as the most commonly diverted prescription opioids analgesics [5, 25] . These data indicate that prescription opioids abuse has steadily increased among heroin and recreational polydrug users since 2000 [5] . An additional concern related to the increased use of prescription opioids is opioid overdose, which increased in the United States from the mid-1990s to the present time [10, 11] and recently became a leading cause of accidental death in the United States [4] . Thus, the risks of prescription opioids abuse and overdose make physicians reluctant to prescribe prescription opioids in general, and access to adequate pain management in drug users in particular is becoming increasingly difficult [20, 39] . In those patients who are prescribed prescription opioids for pain relief, misuse may occur in pain patients with no history of opioid abuse who become dependent on the medications for their reinforcing properties, whether good drug effects or relief of anxiety or mood symptoms, or misuse may occur in drug-seeking individuals with preexisting opioid abuse histories. Thus, balancing the need for effective pain relief and reducing the risks of opioid abuse and overdose remains a challenge for public health policy [7] .
